184 related articles for article (PubMed ID: 20553493)
1. Linking environmental carcinogen exposure to TP53 mutations in human tumours using the human TP53 knock-in (Hupki) mouse model.
Kucab JE; Phillips DH; Arlt VM
FEBS J; 2010 Jun; 277(12):2567-83. PubMed ID: 20553493
[TBL] [Abstract][Full Text] [Related]
2. Applications of the human p53 knock-in (Hupki) mouse model for human carcinogen testing.
Besaratinia A; Pfeifer GP
FASEB J; 2010 Aug; 24(8):2612-9. PubMed ID: 20371617
[TBL] [Abstract][Full Text] [Related]
3. TP53 mutations induced by BPDE in Xpa-WT and Xpa-Null human TP53 knock-in (Hupki) mouse embryo fibroblasts.
Kucab JE; van Steeg H; Luijten M; Schmeiser HH; White PA; Phillips DH; Arlt VM
Mutat Res; 2015 Mar; 773():48-62. PubMed ID: 25847421
[TBL] [Abstract][Full Text] [Related]
4. Metabolic activation of diesel exhaust carcinogens in primary and immortalized human TP53 knock-in (Hupki) mouse embryo fibroblasts.
Kucab JE; Phillips DH; Arlt VM
Environ Mol Mutagen; 2012 Apr; 53(3):207-17. PubMed ID: 22351035
[TBL] [Abstract][Full Text] [Related]
5. Analysis of TP53 mutation spectra reveals the fingerprint of the potent environmental carcinogen, aristolochic acid.
Hollstein M; Moriya M; Grollman AP; Olivier M
Mutat Res; 2013; 753(1):41-49. PubMed ID: 23422071
[TBL] [Abstract][Full Text] [Related]
6. Human tumor p53 mutations are selected for in mouse embryonic fibroblasts harboring a humanized p53 gene.
Liu Z; Hergenhahn M; Schmeiser HH; Wogan GN; Hong A; Hollstein M
Proc Natl Acad Sci U S A; 2004 Mar; 101(9):2963-8. PubMed ID: 14976251
[TBL] [Abstract][Full Text] [Related]
7. The carcinogenic air pollutant 3-nitrobenzanthrone induces GC to TA transversion mutations in human p53 sequences.
vom Brocke J; Krais A; Whibley C; Hollstein MC; Schmeiser HH
Mutagenesis; 2009 Jan; 24(1):17-23. PubMed ID: 18765419
[TBL] [Abstract][Full Text] [Related]
8. TP53 and lacZ mutagenesis induced by 3-nitrobenzanthrone in Xpa-deficient human TP53 knock-in mouse embryo fibroblasts.
Kucab JE; Zwart EP; van Steeg H; Luijten M; Schmeiser HH; Phillips DH; Arlt VM
DNA Repair (Amst); 2016 Mar; 39():21-33. PubMed ID: 26723900
[TBL] [Abstract][Full Text] [Related]
9. UV-induced DNA damage and mutations in Hupki (human p53 knock-in) mice recapitulate p53 hotspot alterations in sun-exposed human skin.
Luo JL; Tong WM; Yoon JH; Hergenhahn M; Koomagi R; Yang Q; Galendo D; Pfeifer GP; Wang ZQ; Hollstein M
Cancer Res; 2001 Nov; 61(22):8158-63. PubMed ID: 11719445
[TBL] [Abstract][Full Text] [Related]
10. Characterising Mutational Spectra of Carcinogens in the Tumour Suppressor Gene
Hölzl-Armstrong L; Kucab JE; Korenjak M; Luijten M; Phillips DH; Zavadil J; Arlt VM
Methods Protoc; 2019 Nov; 2(4):. PubMed ID: 31766274
[TBL] [Abstract][Full Text] [Related]
11. Mutagenicity of acrylamide and glycidamide in human TP53 knock-in (Hupki) mouse embryo fibroblasts.
Hölzl-Armstrong L; Kucab JE; Moody S; Zwart EP; Loutkotová L; Duffy V; Luijten M; Gamboa da Costa G; Stratton MR; Phillips DH; Arlt VM
Arch Toxicol; 2020 Dec; 94(12):4173-4196. PubMed ID: 32886187
[TBL] [Abstract][Full Text] [Related]
12. Unveiling the methylation status of CpG dinucleotides in the substituted segment of the human p53 knock-in (Hupki) mouse genome.
Kim SI; Hollstein M; Pfeifer GP; Besaratinia A
Mol Carcinog; 2010 Dec; 49(12):999-1006. PubMed ID: 20945503
[TBL] [Abstract][Full Text] [Related]
13. Mutagenicity of N-hydroxy-4-aminobiphenyl in human TP53 knock-in (Hupki) mouse embryo fibroblasts.
Hölzl-Armstrong L; Kucab JE; Zwart EP; Luijten M; Phillips DH; Arlt VM
Environ Mol Mutagen; 2021 Apr; 62(4):252-264. PubMed ID: 33620775
[TBL] [Abstract][Full Text] [Related]
14. p53 mutations in benzo(a)pyrene-exposed human p53 knock-in murine fibroblasts correlate with p53 mutations in human lung tumors.
Liu Z; Muehlbauer KR; Schmeiser HH; Hergenhahn M; Belharazem D; Hollstein MC
Cancer Res; 2005 Apr; 65(7):2583-7. PubMed ID: 15805253
[TBL] [Abstract][Full Text] [Related]
15. Aristolactam-DNA adducts are a biomarker of environmental exposure to aristolochic acid.
Jelaković B; Karanović S; Vuković-Lela I; Miller F; Edwards KL; Nikolić J; Tomić K; Slade N; Brdar B; Turesky RJ; Stipančić Ž; Dittrich D; Grollman AP; Dickman KG
Kidney Int; 2012 Mar; 81(6):559-67. PubMed ID: 22071594
[TBL] [Abstract][Full Text] [Related]
16. p53 mutations as fingerprints for aristolochic acid: an environmental carcinogen in endemic (Balkan) nephropathy.
Slade N; Moll UM; Brdar B; Zorić A; Jelaković B
Mutat Res; 2009 Apr; 663(1-2):1-6. PubMed ID: 19428366
[TBL] [Abstract][Full Text] [Related]
17. Formation and repair of DNA lesions in the p53 gene: relation to cancer mutations?
Pfeifer GP; Denissenko MF
Environ Mol Mutagen; 1998; 31(3):197-205. PubMed ID: 9585258
[TBL] [Abstract][Full Text] [Related]
18. Mutagenicity of 2-hydroxyamino-1-methyl-6-phenylimidazo[4,5-b]pyridine (N-OH-PhIP) in human TP53 knock-in (Hupki) mouse embryo fibroblasts.
Hölzl-Armstrong L; Moody S; Kucab JE; Zwart EP; Bellamri M; Luijten M; Turesky RJ; Stratton MR; Arlt VM; Phillips DH
Food Chem Toxicol; 2021 Jan; 147():111855. PubMed ID: 33189884
[TBL] [Abstract][Full Text] [Related]
19. TP53 mutation signature supports involvement of aristolochic acid in the aetiology of endemic nephropathy-associated tumours.
Nedelko T; Arlt VM; Phillips DH; Hollstein M
Int J Cancer; 2009 Feb; 124(4):987-90. PubMed ID: 19030178
[TBL] [Abstract][Full Text] [Related]
20. TP53 Mutational signature for aristolochic acid: an environmental carcinogen.
Moriya M; Slade N; Brdar B; Medverec Z; Tomic K; Jelaković B; Wu L; Truong S; Fernandes A; Grollman AP
Int J Cancer; 2011 Sep; 129(6):1532-6. PubMed ID: 21413016
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
